

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)



(10) International Publication Number
WO 2021/183857 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/022069

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
12 March 2021 (12.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/989,427 13 March 2020 (13.03.2020) US

(71) Applicant: IONIS PHARMACEUTICALS, INC.
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: SCHNEIDER, Eugene; 2855 Gazelle Ct.,
Carlsbad, CA 92010 (US). VINEY, Nicholas, J.; 2855
Gazelle Ct., Carlsbad, CA 92010 (US). ALEXANDER,
Veronica, J.; 2855 Gazelle Ct., Carlsbad, CA 92010 (US).
BORDONE, Laura; 2855 Gazelle Ct., Carlsbad, CA 92010
(US). NEWMAN, Kenneth; 2855 Gazelle Ct., Carlsbad,
CA 92010 (US).

(74) Agent: SCARR, Rebecca B. et al.; McNeill Baur PLLC,
125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PREKALLIKREIN-ASSOCIATED
CONDITIONS

(57) Abstract: Provided herein are methods of administering ISIS 721744 for ameliorating edema, and methods of reducing
prekallikrein (PKK) RNA, protein or activity in a human subject in need thereof. In certain instances, methods are useful for amelio-
rating at least one symptom of hereditary angioedema. Such symptoms of hereditary angioedema include, but are not limited to, nau-
sea, vomiting, itching, headache, fatigue, abdominal pain, shortness of breath, rhinitis, anaphylaxis, bronchoconstriction, and swelling.
In certain instances, methods are useful for ameliorating at least one symptom of macular edema. Such symptoms of macular edema
include, but are not limited to, impaired vision and vision loss.



WO 2021/183857 A1